文献速递乳腺MR

预测HER2零表达与HER2低表达乳腺癌的机器学习模型的开发与验证

Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers.
PubMed 文献 · Br J Radiol · 2024-01-01

本研究基于516例新辅助治疗术后乳腺癌患者的MRI特征,随机分为训练集362例和内部验证集154例,构建逻辑回归、支持向量机、K近邻和XGBoost模型评估HER2状态。XGBoost模型表现最佳,验证集AUC为0.787(95%CI 0.709-0.865),其HER2评分预测病理完全缓解的AUC在训练集为0.708、验证集为0.695,低HER2评分与验证集较短无病生存显著相关(HR 2.748,95%CI 1.016-7.432,P=0.037)。结论认为XGBoost模型有助于区分HER2零表达与HER2低表达乳腺癌,并可能预测新辅助治疗患者的病理完全缓解和预后。

要点

  • XGBoost模型在验证集区分HER2零表达与HER2低表达的AUC为0.787(95%CI 0.709-0.865)。
  • HER2评分预测病理完全缓解的AUC在训练集为0.708、验证集为0.695。
  • 验证集中低HER2评分与较短无病生存显著相关(HR 2.748,95%CI 1.016-7.432,P=0.037)。

核心结论

  • XGBoost模型有助于区分HER2零表达与HER2低表达乳腺癌,并可能预测接受新辅助治疗乳腺癌患者的病理完全缓解和预后。

研究设计与样本

  • 研究纳入516例新辅助治疗后手术的乳腺癌患者,随机分为训练集362例和内部验证集154例,回顾MRI特征并构建逻辑回归、支持向量机、K近邻和XGBoost模型评估HER2状态。

关键影像表现/征象

  • 评估的MRI特征包括肿瘤直径、强化类型、背景实质强化、强化模式、强化百分比、信号强化比、乳腺水肿和表观扩散系数。
  • 表现最佳的XGBoost模型生成HER2评分,该评分与病理完全缓解和无病生存相关。

诊断标准与关键数值

  • XGBoost模型在验证集区分HER2零表达与HER2低表达的AUC为0.783(95%CI 0.733-0.833)和0.787(95%CI 0.709-0.865)。
  • XGBoost模型的HER2评分预测病理完全缓解的AUC在训练集为0.708、验证集为0.695。
  • 验证集中低HER2评分与较短无病生存显著相关(HR 2.748,95%CI 1.016-7.432,P=0.037)。

临床应用与阅片要点

  • XGBoost模型可帮助区分HER2零表达与HER2低表达乳腺癌,并可能预测接受新辅助治疗患者的病理完全缓解和预后。
  • HER2低表达乳腺癌可从HER2靶向治疗中获益,预测HER2低表达对适当管理至关重要。
  • MRI特征为这一临床问题提供了解决方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop and validate machine learning models for human epidermal growth factor receptor 2 (HER2)-zero and HER2-low using MRI features pre-neoadjuvant therapy (NAT).

METHODS: Five hundred and sixteen breast cancer patients post-NAT surgery were randomly divided into training (n = 362) and internal validation sets (n = 154) for model building and evaluation. MRI features (tumour diameter, enhancement type, background parenchymal enhancement, enhancement pattern, percentage of enhancement, signal enhancement ratio, breast oedema, and apparent diffusion coefficient) were reviewed. Logistic regression (LR), support vector machine (SVM), k-nearest neighbour (KNN), and extreme gradient boosting (XGBoost) models utilized MRI characteristics for HER2 status assessment in training and validation datasets. The best-performing model generated a HER2 score, which was subsequently correlated with pathological complete response (pCR) and disease-free survival (DFS).

RESULTS: The XGBoost model outperformed LR, SVM, and KNN, achieving an area under the receiver operating characteristic curve (AUC) of 0.783 (95% CI, 0.733-0.833) and 0.787 (95% CI, 0.709-0.865) in the validation dataset. Its HER2 score for predicting pCR had an AUC of 0.708 in the training datasets and 0.695 in the validation dataset. Additionally, the low HER2 score was significantly associated with shorter DFS in the validation dataset (hazard ratio: 2.748, 95% CI, 1.016-7.432, P = .037).

CONCLUSIONS: The XGBoost model could help distinguish HER2-zero and HER2-low breast cancers and has the potential to predict pCR and prognosis in breast cancer patients undergoing NAT.

ADVANCES IN KNOWLEDGE: HER2-low-expressing breast cancer can benefit from the HER2-targeted therapy. Prediction of HER2-low expression is crucial for appropriate management. MRI features offer a solution to this clinical issue.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Huang X, Wu L, Liu Y, et al. Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers. Br J Radiol. 2024. PMID: 38991838. doi:10.1093/bjr/tqae124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。